Oncology Institute, Inc. (TOIIW)

“The most advanced care should not require travel to a distant hospital. Cancer treatment works best when delivered in the community where patients live.”

The Oncology Institute, Inc. (TOI) has built a network of over 100 community-based cancer treatment clinics across California, Florida, Arizona, Nevada, and Oregon, serving a patient population of more than 1.9 million. Founded in 2007, the company operates a medical practice model that brings highly specialized oncology care — chemotherapy, immunotherapy, radiation therapy, clinical trials — into local communities, thereby reducing the burden on patients and, by design, lowering the total cost of care delivery. The company’s redeemable warrants trade under TOIIW on the NASDAQ.

The community oncology model

Oncology historically concentrated in large hospital systems and academic medical centres. Patients with cancer often travelled significant distances for treatment, losing continuity of care and incurring costs (travel, time away from work) that extended beyond the medical bill itself. TOI inverted that logic. By establishing clinics in suburban and community settings, staffed with employed and affiliate oncologists and supported by nursing, infusion, and support staff, the company made specialized care local. The model has grown to encompass over 180 employed and affiliated clinicians operating across a dispersed network of owned and affiliated locations. This distributed structure is both a strength and a challenge: it allows rapid geographic expansion and community embeddedness, but it fragments operations and makes consistent quality control harder than a unified hospital system would provide.

How the business generates revenue

TOI’s revenue comes from patient care delivery: chemotherapy infusions, radiation therapy planning and administration, blood transfusions, supportive care services, and clinical trial administration. The company bills insurance carriers (commercial, Medicare, Medicaid) for these services at negotiated rates. A portion of revenue is also performance-based, tied to quality metrics and patient outcomes, under value-based care arrangements with certain payers. The centre-based model creates relatively high utilization rates because patients are treated in outpatient settings rather than admitted to hospital, which reduces the cost per treatment episode and allows the company to capture more of the margin between the payer’s reimbursement and the cost of care.

The value-based care bet

TOI’s strategic differentiation is its investment in lowering total cost of care. The company reports that its high-value care program has reduced emergency department visits and hospitalizations by more than half compared to baseline for patients in the program, and saved over $12,000 per patient. These outcomes matter because they demonstrate to payers (insurers, employer health plans) that oncology care delivered in the community setting, with close follow-up and side-effect management, prevents costly hospital admissions. As healthcare reimbursement increasingly ties payment to outcomes rather than fee-for-service volume, the company’s ability to demonstrate cost savings and quality metrics becomes a competitive asset. Payers with large cancer populations are potential customers for TOI’s services under value-based contracting, where savings are shared.

The core tension

TOI’s risk is the gap between the economic theory of community oncology and the operational reality of executing across five dispersed states with over a hundred clinics and a large employed workforce. Community oncology centers lack the scale and capital density of hospital systems, which makes it harder to absorb new equipment, fund clinical research, and retain specialized staff in competitive markets. Reimbursement for oncology is under constant pressure: payers push back on prices, and regulatory changes can shift the economics of specific treatments overnight. TOI’s high utilization model depends on patient compliance with treatment protocols and a stable referral base; if patients churn or referral sources dry up, the fixed costs of clinic operations do not scale down proportionally. The company also carries integration risk: TOI was formed through a merger of The Oncology Institute with DFP Healthcare Acquisitions Corp., and post-merger integration in a geographically dispersed medical practice is operationally complex. Any execution stumbles — lost contracts, clinical quality incidents, staffing instability — can erode the value proposition.

Researching TOI as an investment

Start with the company’s annual 10-K (SEC CIK 0001799191), which discloses patient volumes, revenue per treatment, payer mix (what percentage of revenue comes from Medicare, commercial insurance, and managed care contracts), and the underlying clinical outcomes that support the value-based care pitch. Quarterly earnings calls reveal trends in patient acquisition, clinic utilization rates, and any changes in major payer contracts. Track the company’s operating margins and free cash flow, which indicate whether the model is generating sustainable returns after accounting for clinic overhead and clinical staff costs. Monitor news about regulatory changes in oncology reimbursement and clinical innovations (such as new cancer treatments) that could shift the demand for specific service modalities. Watch also for clinical quality metrics and any litigation or regulatory actions, which can signal operational health in a healthcare business. The warrant position (TOIIW) should be evaluated based on the company’s underlying equity value and the warrant’s exercise terms; call the company’s investor relations office for current dilution and expiration information.